TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00274937
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00936871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single dose
Study: NCT03995732
Drug: PC-SOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
Study: NCT01682083
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
Study: NCT02134405
Drug: Placebo (for Esomeprazole)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Esomeprazole
Study: NCT00778505
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: closed-loop administration using bispectral index as the controller
Study: NCT00778505
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: manual administration according bispectral index values
Study: NCT03497897
Drug: LYS006 2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYS006 2 mg, capsules, oral administration, BID, for 12 weeks
Study: NCT03497897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, capsules, oral administration, BID, for 12 weeks
Study: NCT00914394
Drug: Physiological saline solution (as placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion period 20 minutes
Study: NCT01741844
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).
Study: NCT03995732
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
Study: NCT00723528
Drug: Placebo A (After CP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
Study: NCT01519804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching onartuzumab (MetMAb) placebo iv, Day 1 of each 21-day cycle
Study: NCT00723528
Drug: Placebo B (After CP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
Study: NCT04504396
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
Study: NCT04504396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
Study: NCT00511446
Drug: docetaxel, oxaliplatin, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT04586907
Drug: LY3537021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04586907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT02599714
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
Study: NCT00002549
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00270959
Drug: FDA-Approved Anti-Anxiety Medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
Study: NCT01945528
Drug: US-guided tenotomy with PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood will be drawn from the patient from the patient's unaffected arm. the anti-coagulated blood will be centrifuged and pure-PRP (without leukocytes) collected.~Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; PRP will be delivered in multiple depots during the procedure
Study: NCT01449630
Drug: LY3031207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01449630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01449630
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02430870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-648 placebo-matching solution
Study: NCT02979015
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT00105196
Drug: Placebo+ ADT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
Study: NCT03037372
Drug: ART, Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART, Rosuvastatin
Study: NCT03037372
Drug: ART, No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART, No statin
Study: NCT03037372
Drug: Healthy-HIV-negative
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-matched, Healthy HIV-negative
Study: NCT02183688
Drug: Low dose ASA
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183688
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01285037
Drug: LY2801653
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2801653 given orally once daily during 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Study: NCT01361048
Drug: neo penotran forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: neo penotran forte intravaginal twice a day for 7 days
Study: NCT01361048
Drug: neo penotran forte once a day
Approvals — FDA: no, EMA: no, PMDA: no
Description: neo penotran forte intravaginally once a day for 7 days
Study: NCT03005522
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosed with placebo
Study: NCT00626223
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg per day of oral folic acid
Study: NCT01423318
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose subcutaneously
Study: NCT01895296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo s.c.
Study: NCT01414881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously (SC) once weekly
Study: NCT03960970
Drug: Azithromycin 500 mg
Normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Additional IV Azithromycin 500 mg to Standard Prophylaxis
Study: NCT02095860
Drug: DCV 3DAA FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325
Study: NCT04285749
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvastatin PO 80mg QD for 2 weeks
Study: NCT03382548
Drug: Reducing Antibiotics treatment duration
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics should be stopped from day 3 to 7 if respiratory cultures are negative and the patients fulfill a set of stringent clinical criteria signifying cardiopulmonary stability for 48 hours. If the respiratory cultures are positive, patients who fulfill the same set of clinical criteria should have their antibiotics stopped from day 5 to 7.
Study: NCT03382548
Drug: Standard Antibiotics treatment duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the control (long duration) arm will receive standard care, which is antibiotic treatment for at least 8 days with the exact duration decided by the primary physician.
Study: NCT00905853
Drug: Escalated Antiarrhythmic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.~Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.~Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day
Study: NCT02069665
Drug: Xiyanping injection
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
Study: NCT02069665
Drug: Xiaoer Qingfei Heji (mixture)
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;
Study: NCT02069665
Drug: Zhi Ke San
Approvals — FDA: no, EMA: no, PMDA: no
Description: children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
Study: NCT02069665
Drug: Hua Tan San
Approvals — FDA: no, EMA: no, PMDA: no
Description: children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
Study: NCT02069665
Drug: Ibuprofen Suspension
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: taken under prescription
Study: NCT00346814
Drug: intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02495844
Drug: UCB0942
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use
Study: NCT02495844
Drug: UCB0942
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use
Study: NCT02495844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral use
Study: NCT02305758
Drug: Modified FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) on Day 1 of each 14-day cycle
Study: NCT02305758
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m\^2 (up to 15-minute infusion) on Day 1 of each 14-day cycle
Study: NCT02305758
Drug: Fluorouracil infusion
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2400 mg/m\^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle
Study: NCT01110616
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, to match MK3134, and placebo to match Lorazepam
Study: NCT02285920
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
Study: NCT00549939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: matching solution or matching tablet according to age~Route: oral~Dose: daily dose adjusted to body weight
Study: NCT00159757
Drug: ziprazidone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01360554
Drug: Placebo PF00299804
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing
Study: NCT04223843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Inhalation
Study: NCT00698724
Drug: Xibrom and Pred Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xibrom: two drops a day, three days before surgery and 21 days after surgery. Pred Forte: three times a day for 21 days after surgery.
Study: NCT01312038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: chewable calcium tablet
Study: NCT01856426
Drug: EDP239
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01856426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01848340
Drug: 150 mg GSK1265744B
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet
Study: NCT01848340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet
Study: NCT04186845
Drug: rhPSMA-7.3 (18F) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioligand for PET CT scanning
Study: NCT02865122
Drug: NTRA-9620
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily dose
Study: NCT02865122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily dose
Study: NCT02388620
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg
Study: NCT03093883
Drug: Ferrinemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
Study: NCT00834171
Drug: Loteprednol etabonate (0.5%) and tobramycin (0.3%).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.
Study: NCT02351024
Drug: OXP005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02351024
Drug: Naprosyn®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01860404
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
Study: NCT01450995
Drug: Imitrex and two Aleve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
Study: NCT03931161
Drug: Placebo Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for the active comparator (Evolocumab)
Study: NCT03726866
Drug: Sequence 5
Normalized name: antihemophilic factor VIII, recombinant porcine sequence 500 (+/-) unit range INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D326, D337 or CKD-828 for 9 days
Study: NCT01356693
Drug: Bromelin
Normalized name: Bromelin specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ananas comosus extract (3,3g) on vehicle: methylparaben, propylparaben, honey from Apis mellifera, sodium benzoate, ethilic alcohol, water) 5ml. Given in single dose.
Study: NCT01356693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with mimicking characteristics of experimental drug
Study: NCT02332499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo p.o. qd
Study: NCT00324168
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization
Study: NCT00324168
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
Study: NCT04597450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
Study: NCT00040638
Drug: TLK286
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00324168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
Study: NCT02769637
Drug: PPI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI treatment or no PPI treatment
Study: NCT04159142
Drug: Nab-paclitaxel + Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and capecitabine given IV at 1000 mg/m\^2 bid, d1-14 every 21 days x 6 cycles；
Study: NCT00461344
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01232543
Drug: Product 0405
Normalized name: Pyelocalyceal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product 0405 will be administered topically, twice daily for 28 days.
Study: NCT03649841
Drug: Antiandrogen Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo ADT
Study: NCT01529060
Drug: Placebo powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.
Study: NCT01449513
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel vehicle of PEP005
Study: NCT03952143
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03044938
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral preparation for pharmacological effects, given in substitution of a medicine, for the purpose of provoking or controlling reactions, ger. Of a psychological nature, accompanying such a therapeutic procedure.
Study: NCT02562365
Drug: Etoposide, Cyclophosphamide, Carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5)+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
Study: NCT02865564
Drug: ampicillin and gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01926548
Drug: Gleevec film-coated tablet 2 x 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03060044
Drug: Seretide Diskus with charcoal
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01986920
Drug: A-101 25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Concentration of A-101 applied to one of 4 Target Lesions
Study: NCT01986920
Drug: A-101 32.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
Study: NCT01986920
Drug: A-101 40%
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Concentration A-101 applied to one of 4 Target Lesions
Study: NCT01359566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for arbaclofen placarbil 15, 30 and 45 mg BID
Study: NCT00535951
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00182312
Drug: Caffeine citrate injection
Normalized name: Caffeine Citrate Injection
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy.
Study: NCT03469583
Drug: EYP001
Approvals — FDA: no, EMA: no, PMDA: no
Description: EYP001 self administered capsules, morning, with non carbonated water